Nasonex Sales Data
| Rank 53 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Nasonex U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 53 ( 1) |
$272,345 | 5.67% | 2,105 | -1.41% |
| Q3 2013 | 54 ( 10) |
$257,743 | -11.64% | 2,135 | -19.59% |
| Q2 2013 | 44 (2) |
$291,694 | 2.75% | 2,655 | n/a |
| Q1 2013 | 46 (9) |
$283,875 | 8.87% | 2,655 | 4.32% |
| Q4 2012 | 55 (6) |
$260,739 | 5.44% | 2,545 | 3.12% |
| Q3 2012 | 61 (9) |
$247,294 | -9.30% | 2,468 | -10.19% |
| Q2 2012 | 52 (4) |
$272,661 | -0.76% | 2,748 | -2.48% |
| Q1 2012 | 56 (8) |
$274,748 | 9.21% | 2,818 | 5.31% |
| Q4 2011 | 64 (4) |
$251,582 | 9.30% | 2,676 | 8.08% |
| Q3 2011 | 68 (17) |
$230,174 | -14.77% | 2,476 | -16.18% |
| Q2 2011 | 51 (4) |
$270,076 | 0.96% | 2,954 | 0.75% |
| Q1 2011 | 55 | $267,495 | n/a | 2,932 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
